Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients

J Physiol Pharmacol. 2014 Aug;65(4):543-50.


The relationship between the prevalence of multiple sclerosis (MS) and sunlight's ultraviolet radiation was proved. Oxidative stress plays a role in the pathogenic traits of MS. Melatonin possesses antioxidative properties and regulates circadian rhythms. Several studies have reported that the quality of life is worse in patients with MS than in healthy controls, with a higher prevalence of sleep disturbances, depression and fatigue. The aim of study was to evaluate 5 mg daily melatonin supplementation over 90 days on serum malondialdehyde (MDA) concentration and superoxide dismutase (SOD) activity and its' influence on impact of the quality of life of MS patients. A case-control prospective study was performed on 102 MS patients and 20 controls matched for age and sex. The EDSS, MRI examinations and Multiple Sclerosis Impact Scale (MSIS-29) questionnaire was completed. Marked increase in serum MDA concentration in all MS patients groups was observed and after melatonin treatment decreased significantly in interferons-beta and glatiramer acetate-treated groups, but not in mitoxantrone-treated group. A significant increase in SOD activity compared to controls only in glatiramer acetate-treated group was observed. After 3 months melatonin supplementation the SOD activity increased compared to initial values in interferons beta-treated groups. A significant increase in both MSIS-29-PHYS and MSIS-29-PSYCH items mean scores only in the MX group as compared to other groups was observed. There were no significant differences in mean MSIS-29-PHYS was observed before and after melatonin therapy. Melatonin supplementation caused a decrease in mean MSIS-29-PSYCH scores compared to initial values in interferons beta-treated groups. Finding from our study suggest that melatonin can act as an antioxidant and improves reduced quality in MS patients.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Adult
  • Antioxidants / pharmacology*
  • Dietary Supplements
  • Female
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon-beta / therapeutic use
  • Male
  • Malondialdehyde / blood*
  • Melatonin / pharmacology*
  • Middle Aged
  • Mitoxantrone / therapeutic use
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / psychology*
  • Neuropsychological Tests
  • Peptides / therapeutic use
  • Quality of Life
  • Severity of Illness Index
  • Superoxide Dismutase / blood*
  • Young Adult


  • Adjuvants, Immunologic
  • Antioxidants
  • Immunosuppressive Agents
  • Peptides
  • Interferon beta-1b
  • Malondialdehyde
  • Glatiramer Acetate
  • Interferon-beta
  • Mitoxantrone
  • Superoxide Dismutase
  • Melatonin
  • Interferon beta-1a